MURANO, a randomized phase III study sponsored by Abbvie, showed that patients with relapsed or refractory chronic lymphocytic leukemia achieved significantly prolonged median progression-free survival with Venclexta/Venclyxto (venetoclax) in combination with Rituxan (rituximab) [median PFS, not reached], compared with bendamustine in combination with Rituxan [median PFS, 17.0 months; hazard ratio, 0.17; 95% CI, 0.11–0.25; P<0.0001].
A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.
